Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Mizuho Fukunaba-Kalabis"'
Autor:
Jessie Villanueva, Jeffrey R. Infante, Clemens Krepler, Patricia Reyes-Uribe, Minu Samanta, Hsin-Yi Chen, Bin Li, Rolf K. Swoboda, Melissa Wilson, Adina Vultur, Mizuho Fukunaba-Kalabis, Bradley Wubbenhorst, Thomas Y. Chen, Qin Liu, Katrin Sproesser, Douglas J. DeMarini, Tona M. Gilmer, Anne-Marie Martin, Ronen Marmorstein, David C. Schultz, David W. Speicher, Giorgos C. Karakousis, Wei Xu, Ravi K. Amaravadi, Xiaowei Xu, Lynn M. Schuchter, Meenhard Herlyn, Katherine L. Nathanson
Publikováno v:
Cell Reports, Vol 4, Iss 6, Pp 1090-1099 (2013)
Although BRAF and MEK inhibitors have proven clinical benefits in melanoma, most patients develop resistance. We report a de novo MEK2-Q60P mutation and BRAF gain in a melanoma from a patient who progressed on the MEK inhibitor trametinib and did not
Externí odkaz:
https://doaj.org/article/def1fcb2813549cea0a237cf8e63bb48
Autor:
Qin Liu, Patricia Reyes-Uribe, Tona M. Gilmer, Douglas J. DeMarini, Melissa Wilson, Bin Li, Adina Vultur, Meenhard Herlyn, Rolf Swoboda, Hsin-Yi Chen, Mizuho Fukunaba-Kalabis, Jeffrey R. Infante, Anne-Marie Martin, Thomas Y. Chen, Ronen Marmorstein, Jessie Villanueva, Clemens Krepler, David C. Schultz, Minu Samanta, Lynn M. Schuchter, Wei Xu, Katrin Sproesser, Xiaowei Xu, Bradley Wubbenhorst, Ravi K. Amaravadi, Katherine L. Nathanson, Giorgos C. Karakousis, David W. Speicher
Publikováno v:
Cell Reports, Vol 4, Iss 6, Pp 1090-1099 (2013)
SummaryAlthough BRAF and MEK inhibitors have proven clinical benefits in melanoma, most patients develop resistance. We report a de novo MEK2-Q60P mutation and BRAF gain in a melanoma from a patient who progressed on the MEK inhibitor trametinib and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7eae2cd251fb405dcdcf8ac84d3b0c3
http://www.sciencedirect.com/science/article/pii/S2211124713004646
http://www.sciencedirect.com/science/article/pii/S2211124713004646